SCN8A self-limited infantile epilepsy: Does epilepsy resolve?

Area of Science:

• Genetics
• Neurology
• Pediatrics

Background:

• SCN8A gene variants are associated with a spectrum of epilepsy phenotypes.
• Self-limited infantile epilepsy (SeLIE) typically begins in infancy and resolves by age three.
• The natural history of epilepsy resolution in SCN8A-SeLIE requires further investigation.

Purpose of the Study:

• To determine the age of epilepsy resolution in individuals with SCN8A-related SeLIE.
• To characterize the long-term seizure progression and treatment response in SCN8A-SeLIE.

Main Methods:

• Detailed phenotyping of unpublished individuals with SCN8A-SeLIE.
• Systematic literature review of published SCN8A-SeLIE cases with seizure progression data.
• Analysis of seizure offset age and medication use.

Main Results:

• More than half of individuals with SCN8A-SeLIE experience persistent seizures beyond age three.
• In the combined cohort (unpublished and published), 36% had seizures after age ten.
• Despite being drug-responsive, five of six unpublished individuals remained on antiseizure medications, with seizure offset ranging from 4 to 21 years.

Conclusions:

• SCN8A-SeLIE often presents a more persistent epilepsy phenotype compared to SeLIE from other causes.
• Epilepsy resolution in SCN8A-SeLIE frequently extends into late childhood.
• Long-term management with antiseizure medications is often necessary for SCN8A-SeLIE.